| Ytd | 297.04% | |
| 1y | 689.84% |
| Open | 15.41 | Prev Close | 15.34 | Low | 14.51 | High | 15.41 | Mkt Cap | 5.17B |
| Vol | 8.69M | Avg Vol | 4.59M | EPS | -0.95 | P/E | N/A | Forward P/E | -23.70 |
| Beta | 0.65 | Short Ratio | 9.70 | Inst. Own | 86.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 17.93 | 200-d Avg | 13.36 | 1yr Est | 24.11 |
ERAS News
Engineers Gate Manager LP bought a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pr
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHILADELPHIA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is i
Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional pati
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precisio
Frazier Life Sciences Management L.P. raised its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 1
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized invest
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recogn
BlackRock Inc. acquired a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter, accordi
The Alger Mid Cap 40 ETF outperformed the Russell Midcap Growth Index during the second quarter of 2
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X
New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recogn
Handelsbanken Fonder AB bought a new position in shares of Erasca, Inc. (NASDAQ: ERAS) during the se
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises
Guggenheim analyst Paul Jeng maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price targe
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and
Bank of America Corp DE increased its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 89.6% in the
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consens
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PD
New York, New York--(Newsfile Corp. - August 10, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - August 10, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nat
LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors Have Opportunity to Lead Erasca, Inc. Securit
Morgan Stanley analyst Sean Laaman maintains Erasca (NASDAQ:ERAS) with a Equal-Weight and raises
Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discov
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic canc
Top analysts upgrade MUR, UNH, ESNT, and ERAS stocks. For more rating changes, see analyst ratings p
B of A Securities analyst Alec Stranahan upgrades Erasca (NASDAQ:ERAS) from Underperform to Neutr
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
Mizuho analyst Joseph Catanzaro maintains Erasca (NASDAQ:ERAS) with a Outperform and lowers the p
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.60) per share which missed the analyst consens
This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecul
US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate
US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy
Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines'
US stock futures mixed, Nasdaq down 1%. Rambus Inc (NASDAQ: RMBS) shares fall 15.1% pre-market after
Shares of Bed Bath & Beyond (BBBY) rose 23.4% in pre-market trading after beating revenue estima
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/
On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. (
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discov
Stifel analyst Laura Prendergast maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price t
On April 21, 2026, Erasca, Inc. (the "Company") narrowed the time period for the anticipated
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen